Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 14
Treatment-assignment count: 2
Stratification count: 0
Trial Selection Rising
RET fusion
gastric cancer · Monoclonal Antibody
RET fusion is flagged as trial selection rising because public trials show inclusion required evidence in 17 contexts. FDA CDx context should be reviewed manually. Threshold text varies across public records.
Threshold snippets
Fragmentation view
Threshold count: 18
Common snippets: dMMR | dMMR | MSI-H
Threshold label: Fragmented
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02757391 | https://clinicaltrials.gov/study/NCT01641939 | https://clinicaltrials.gov/study/NCT05113459 | https://clinicaltrials.gov/study/NCT07334431 | https://clinicaltrials.gov/study/NCT05608785 | https://clinicaltrials.gov/study/NCT06468280 | https://clinicaltrials.gov/study/NCT04744649 | https://clinicaltrials.gov/study/NCT05468138 | https://clinicaltrials.gov/study/NCT04030260 | https://clinicaltrials.gov/study/NCT06099821 | https://clinicaltrials.gov/study/NCT07581574 | https://clinicaltrials.gov/study/NCT05104567 | https://clinicaltrials.gov/study/NCT04082364 | https://clinicaltrials.gov/study/NCT06792162 | https://clinicaltrials.gov/study/NCT04098796 | https://clinicaltrials.gov/study/NCT04581473 | https://clinicaltrials.gov/study/NCT04495296